Ambit's powerful profiling technology, innovative licensing strategy, history of kinase expertise and pipeline of cancer therapeutics are making news.
12.09.08Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
04.23.08High Throughput Kinase Screening Expedites Drug Discovery and Development
Our proprietary kinase profiling platform, KinomeScan, turns the promiscuity of kinase inhibitors into a key discovery and development advantage.
More Info »
Click here for downloadable KinomeScan Fact Sheet
More Info »
Click here for downloadable KinomeScan Fact Sheet
Our lead compound AC220, a small molecule kinase inhibitor for the
treatment of Acute Myeloid Leukemia, entered the clinic in 2006.
From profiling services to clinical development expertise, find out what Ambit has to offer.
